Technical Analysis for NCNA - NuCana plc
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| See historical NCNA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Sep 20 | Crossed Above 50 DMA | Bullish | 0.00% |
| Sep 20 | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% |
| Sep 20 | Outside Day | Range Expansion | 0.00% |
| Sep 19 | Fell Below 50 DMA | Bearish | 1.80% |
| Sep 19 | 180 Bearish Setup | Bearish Swing Setup | 1.80% |
| Sep 19 | Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 1.80% |
| Sep 19 | Narrow Range Bar | Range Contraction | 1.80% |
| Sep 19 | Outside Day | Range Expansion | 1.80% |
| Sep 18 | 50 DMA Support | Bullish | -0.59% |
| Sep 18 | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -0.59% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Pharmaceuticals
NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more NCNA news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 32.0 |
| 52 Week Low | 9.32 |
| Average Volume | 31,811 |
| 200-Day Moving Average | 21.371 |
| 50-Day Moving Average | 23.5819 |
| 20-Day Moving Average | 24.2083 |
| 10-Day Moving Average | 23.5665 |
| Average True Range | 1.5103 |
| ADX | 11.32 |
| +DI | 13.7469 |
| -DI | 17.6366 |
| Chandelier Exit (Long, 3 ATRs ) | 25.5691 |
| Chandelier Exit (Short, 3 ATRs ) | 26.6109 |
| Upper Bollinger Band | 26.413 |
| Lower Bollinger Band | 22.0036 |
| Percent B (%b) | 0.4 |
| BandWidth | 18.214414 |
| MACD Line | -0.1138 |
| MACD Signal Line | -0.0376 |
| MACD Histogram | -0.0763 |
| Fundamentals | Value |
|---|---|
| Market Cap | 756.47 Million |
| Num Shares | 31.8 Million |
| EPS | -0.40 |
| Price-to-Earnings (P/E) Ratio | -59.45 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 0.00 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 25.16 | ||||
| Resistance 3 (R3) | 25.10 | 24.57 | 24.93 | ||
| Resistance 2 (R2) | 24.57 | 24.22 | 24.61 | 24.85 | |
| Resistance 1 (R1) | 24.18 | 24.00 | 24.38 | 24.24 | 24.78 |
| Pivot Point | 23.65 | 23.65 | 23.75 | 23.69 | 23.65 |
| Support 1 (S1) | 23.26 | 23.30 | 23.46 | 23.32 | 22.78 |
| Support 2 (S2) | 22.73 | 23.08 | 22.77 | 22.71 | |
| Support 3 (S3) | 22.34 | 22.73 | 22.63 | ||
| Support 4 (S4) | 22.40 |
